Why Tirzepatide May Change Your Period There are several reasons tirzepatide and menstrual cycle changes may happen
Alanine scanning of a putative receptor binding surface of insulin-like growth factor-I
Exenatide (Byetta) became the first GLP-1 receptor agonist approved by the FDA on April 29, 2005, for type 2 diabetes
Week 13+: 12mg/week (if needed) Maximum dose for those who plateau at 8mg
However, these methods may carry additional risks and require careful consideration of injection technique, sterility, and absorption kinetics
Practitioners may consider AOD 9604 in investigational protocols where IGF-1 elevation is a concern, recognizing that AOD 9604 has no regulatory approval and a narrower, largely preclinical record of efficacy